DailyMed

Patients,dose,reactions,adverse reaction rates,study,exposure,risks.

Uncertain size,causal relationship,trial,background risk,major birth defects,human milk,relationship to drug exposure,pain.

FDA-approved patient labeling,impairment,toxicities,animal reproduction studies,subject,Abdominal pain,human dose,potential risk,DRUGItem Code,reproductive potential,single dose,Embryo-fetal toxicities.

Dose adjustment,fetal harm,shortness of breath,seeAdverse Reactions,systemic exposure,Renal Impairment,myocardial infarction,breastfed infant,pediatric patients,clinical trial,grade,healthy subjects,Dosage and Administration,oral administration,Musculoskeletal pain,titanium dioxide,treatment of adult patients,human exposure,unacceptable toxicity,dosage adjustment,treatment of patients,oral dose,hepatic impairment,adjustments,single-dose vial,renal function,weeks of treatment,placebo arm,placebo-treated patients,daily dose,Drug Interactions,seeAdverse Reactions,medical attention,cynomolgus monkeys,performance status,percent of patients,initial dose,injection site reactions,Grade 3,administration,active metabolite,female partners,dose interruption,peripheral neuropathy,clinical exposure,Pediatric Subjects,Adverse Reactions,infusion-related reaction,Study 1,Grade 4,100 subject-years,NEXAVAR-treated patients,XTANDI-treated patients,Ps STUDY,NHL Study,CSU Trial.